7-5/2018/EU/WC-0422 Government of India Directorate General of Health Services Central Drugs Standard Control Organisation (International Cell)

FDA Bhawan, Kotla Road, New Delhi-110002 Dated:

10 5 JAN 2007

To.

M/s. Sai-tech Pharmaceuticals Pvt. Ltd., Plot No. A-145/8, Khairane, M.I.D.C. Industrial Area, Navi Mumbai-400705, Taluka-Koparkhairane, District-Thane, Maharashtra, India

SUB:- Written Confirmation of M/s. Sai-tech Pharmaceuticals Pvt. Ltd., Plot No. A-145/8, Khairane, M.I.D.C. Industrial Area, Navi Mumbai-400705, Taluka-Koparkhairane, District-Thane, Maharashtra, India as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your online application no. WC/FR/2021/755 submitted to CDSCO, West Zone office and the recommendation received from DDC(I), West Zonal office on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

- 1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
- The manufacturer is subject to regular, strict and transparent controls and to the
 effective enforcement of Good Manufacturing Practice, including repeated and
 unannounced inspections, so as to ensure a protection of public health
 equivalent to that in the EU.
- The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
- 4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.

- 5. The Written Confirmation will be withdrawn in the events of non compliance of Standards.
- 6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.
- 7: In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
- 8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
	03	09.09.2021	07.06.2024
01	01	0.5 IAN 2022	07.06.2024

Yours faithfully,

(Dr. V. G. Somani) Drugs Controller General (India)

Midalar



GOVERNMENT OF INDIA MINISTRY OF HEALTH & FAMILY WELFARE Central Drugs Standard Control Organization

CERTIFICATE NO.:

WC-0422

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s. Sai-Tech Pharmaceuticals Pvt. Ltd.

Plot No: A-145/8, Khairane M.I.D.C. Industrial Area, Navi Mumbai – 400 705, Taluka – Koparkhairane,

District – Thane, Maharashtra, India

List of APIs:

S. No.	Active substance(s)	Activity(ies)
	Butamirate Citrate IH	Manufacturing & Packing

ITEM(S) One (01) Only

This certificate is being issued subject to condition that the firm shall obtain NOC from the Competent Authority, on case to case basis, to manufacture the above mentioned active substances for the purpose of export only, as the above mentioned active substances are not approved for manufacture for sale in India.

The Written Confirmation remains valid until: 07th June, 2024

Signature Vin

date Stam!

05 JAN 2022